Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 51 clinical trials
None
TCD Followed by autoSCT for Newly Diagnosed MM Patients

Multiple Myeloma is a incurable disease. Thalidomide in combination with other agents are currently in trials for the newly diagnosed patients, we designed treatment of TCD, followed by

cell transplantation
maintenance therapy
thalidomide
high dose chemotherapy
  • 5 views
  • 07 Nov, 2020
  • 1 location
None
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction Follow by Dara Consolidation

drugs combo did not prove gain against three drugs One of the three drugs protocol studied as induction was CTD scheme (cyclophosphamide+ thalidomide+dexamethasone). Daratumumab has a novel mechanism of

  • 0 views
  • 22 Jan, 2021
  • 1 location
None
Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM

1. Primary Objective To assess the response rate of sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Velcade, Thalidomide, Dexamethasone) induction therapy as a

cell transplantation
velcade
dexamethasone
thalidomide
platelet count
  • 7 views
  • 07 Nov, 2020
  • 1 location
None
Lenalidomide and Dexamethasone for Rosai-Dorfman Disease

based on retrospective study. Steroid was suggested as frontline treatment as RDD with only lymph nodes involvement. Studies showed thalidomide or lenalidomide showed some effect in recurrent/refractory

  • 0 views
  • 28 Jun, 2021
  • 1 location
None
PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma

Prospective multicenter phase 2 study using PAD and Thal/Dex combination sequentially.

cell transplantation
velcade
dexamethasone
thalidomide
refractory multiple myeloma
  • 6 views
  • 07 Nov, 2020
  • 1 location
None
Pomalidomide for the Treatment of Bleeding in HHT

This is a Phase II placebo-controlled double-blind study of pomalidomide in patients with hereditary hemorrhagic telangiectasia (HHT) with moderate to severe epistaxis who require parenteral iron infusions or blood transfusions. A total of 159 patients will be randomized 2:1 to treatment with oral pomalidomide or matching placebo for 24 weeks. …

epistaxis
pomalyst
iron
platelet count
blood transfusion
  • 1 views
  • 22 Jul, 2021
  • 10 locations
None
Multi-center Trial of Revlimid and Rituximab for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

The study is a two-arm, multi-center trial of Revlimid® and Rituximab, for the frontline treatment of patients with Chronic Lymphocytic Leukemia (CLL) designed and conducted by the CLL Research Consortium (CRC). The purpose of this study is to determine the response rate of the combination of Revlimid® and Rituximab in …

lymphoid leukemia
cancer
platelet count
rituximab
lenalidomide
  • 42 views
  • 07 Nov, 2020
  • 3 locations
None
Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular Carcinoma

Background Hepatocellular carcinoma, a malignant tumor of liver is one of the most common cancers worldwide. All India Institute Of Medical Sciences (AIIMS) being a tertiary care hospital receives about two to three cases of Hepatocellular carcinoma (HCC) each day in our Gastroenterology out patient department. Most of these patients …

cancer
chemoembolization
unresectable hepatocellular carcinoma
cirrhosis
TACE
  • 30 views
  • 07 Nov, 2020
  • 1 location
None
A Randomised Trial of Cabazitaxel Docetaxel Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients Without Metastasis

Current agents administered in therapeutic regimens of prostate cancer employ different mechanisms to eliminate neoplastic cells by inducing substantial apoptosis and causing tumor regression. Treatment with neoadjuvant chemotherapy before radical prostatectomy may better control the tumor before it has the chance to convert into the disease of castration-resistant prostate cancer …

  • 5 views
  • 26 Jan, 2021
  • 2 locations
None
Daratumumab Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma

patients with myeloma. The use of immunomodulatory drugs, such as thalidomide and lenalidomide, has been shown to augment NK cell activity. NK cells are important mediator of antibody dependent cellular

  • 81 views
  • 22 Jan, 2021
  • 3 locations